Twist Bioscience Co. (NASDAQ:TWST) CFO James M. Thorburn sold 8,000 shares of Twist Bioscience stock in a transaction dated Tuesday, June 8th. The stock was sold at an average price of $103.38, for a total transaction of $827,040.00. Following the completion of the sale, the chief financial officer now owns 54,732 shares of the company’s stock, valued at approximately $5,658,194.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
TWST stock opened at $111.67 on Friday. Twist Bioscience Co. has a 12 month low of $35.50 and a 12 month high of $214.07. The company has a market cap of $5.46 billion, a price-to-earnings ratio of -41.21 and a beta of 0.69. The firm has a 50-day moving average price of $115.40.
Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Thursday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.02). The company had revenue of $31.20 million for the quarter, compared to the consensus estimate of $28.18 million. Twist Bioscience had a negative net margin of 109.15% and a negative return on equity of 25.47%. The company’s revenue for the quarter was up 61.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.85) earnings per share. Analysts anticipate that Twist Bioscience Co. will post -3.02 earnings per share for the current fiscal year.
Several brokerages have weighed in on TWST. Zacks Investment Research upgraded shares of Twist Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, April 8th. The Goldman Sachs Group initiated coverage on shares of Twist Bioscience in a research note on Friday, June 4th. They issued a “neutral” rating and a $110.00 price objective for the company. Finally, Piper Sandler initiated coverage on shares of Twist Bioscience in a report on Monday, April 12th. They issued an “overweight” rating and a $150.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. Twist Bioscience presently has an average rating of “Hold” and an average target price of $132.00.
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
See Also: Index Funds
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.